Literature DB >> 25972560

Cooperativity of HIV-Specific Cytolytic CD4 T Cells and CD8 T Cells in Control of HIV Viremia.

Susan Johnson1, Michael Eller1, Jeffrey E Teigler1, Sebastien M Maloveste1, Bruce T Schultz1, Damien Z Soghoian2, Richard Lu1, Alexander F Oster1, Agnès-Laurence Chenine1, Galit Alter2, Ulf Dittmer3, Mary Marovich1, Merlin L Robb1, Nelson L Michael1, Diane Bolton1, Hendrik Streeck4.   

Abstract

UNLABELLED: CD4+ T cells play a pivotal role in the control of chronic viral infections. Recently, nontraditional CD4+ T cell functions beyond helper effects have been described, and a role for cytolytic CD4+ T cells in the control of HIV infection has been suggested. We define here the transcriptional, phenotypic, and functional profiles of HIV-specific cytolytic CD4+ T cells. Fluidigm BioMark and multiparameter flow cytometric analysis of HIV-specific cytolytic CD4+ T cells revealed a distinct transcriptional signature compared to Th1 CD4+ cells but shared similar features with HIV-specific cytolytic CD8+ T cells. Furthermore, HIV-specific cytolytic CD4+ T cells showed comparable killing activity relative to HIV-specific CD8+ T cells and worked cooperatively in the elimination of virally infected cells. Interestingly, we found that cytolytic CD4+ T cells emerge early during acute HIV infection and tightly follow acute viral load trajectory. This emergence was associated to the early viral set point, suggesting an involvement in early control, in spite of CD4 T cell susceptibility to HIV infection. Our data suggest cytolytic CD4+ T cells as an independent subset distinct from Th1 cells that show combined activity with CD8+ T cells in the long-term control of HIV infection. IMPORTANCE: The ability of the immune system to control chronic HIV infection is of critical interest to both vaccine design and therapeutic approaches. Much research has focused on the effect of the ability of CD8+ T cells to control the virus, while CD4+ T cells have been overlooked as effectors in HIV control due to the fact that they are preferentially infected. We show here that a subset of HIV-specific CD4+ T cells cooperate in the cytolytic control of HIV replication. Moreover, these cells represent a distinct subset of CD4+ T cells showing significant transcriptional and phenotypic differences compared to HIV-specific Th1 cells but with similarities to CD8+ T cells. These findings are important for our understanding of HIV immunopathology.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25972560      PMCID: PMC4505667          DOI: 10.1128/JVI.00438-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans.

Authors:  Tom M Wilkinson; Chris K F Li; Cecilia S C Chui; Arthur K Y Huang; Molly Perkins; Julia C Liebner; Rob Lambkin-Williams; Anthony Gilbert; John Oxford; Ben Nicholas; Karl J Staples; Tao Dong; Daniel C Douek; Andrew J McMichael; Xiao-Ning Xu
Journal:  Nat Med       Date:  2012-01-29       Impact factor: 53.440

Review 2.  Genetic and epigenetic networks controlling T helper 1 cell differentiation.

Authors:  Katarzyna Placek; Maryaline Coffre; Sylvie Maiella; Elisabetta Bianchi; Lars Rogge
Journal:  Immunology       Date:  2009-06       Impact factor: 7.397

3.  Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.

Authors:  Naomi N Hunder; Herschel Wallen; Jianhong Cao; Deborah W Hendricks; John Z Reilly; Rebecca Rodmyre; Achim Jungbluth; Sacha Gnjatic; John A Thompson; Cassian Yee
Journal:  N Engl J Med       Date:  2008-06-19       Impact factor: 91.245

4.  CD134 plus CD137 dual costimulation induces Eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation.

Authors:  Harry Z Qui; Adam T Hagymasi; Suman Bandyopadhyay; Marie-Clare St Rose; Raghunath Ramanarasimhaiah; Antoine Ménoret; Robert S Mittler; Scott M Gordon; Steven L Reiner; Anthony T Vella; Adam J Adler
Journal:  J Immunol       Date:  2011-08-31       Impact factor: 5.422

5.  Ectopic expression of a T-box transcription factor, eomesodermin, renders CD4(+) Th cells cytotoxic by activating both perforin- and FasL-pathways.

Authors:  Koji Eshima; Sayuri Chiba; Harumi Suzuki; Kenichi Kokubo; Hirosuke Kobayashi; Misao Iizuka; Kazuya Iwabuchi; Nobukata Shinohara
Journal:  Immunol Lett       Date:  2012-03-10       Impact factor: 3.685

6.  HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome.

Authors:  Damien Z Soghoian; Heiko Jessen; Michael Flanders; Kailan Sierra-Davidson; Sam Cutler; Thomas Pertel; Srinika Ranasinghe; Madelene Lindqvist; Isaiah Davis; Kimberly Lane; Jenna Rychert; Eric S Rosenberg; Alicja Piechocka-Trocha; Abraham L Brass; Jason M Brenchley; Bruce D Walker; Hendrik Streeck
Journal:  Sci Transl Med       Date:  2012-02-29       Impact factor: 17.956

7.  Functional and phenotypic characterization of CD57+CD4+ T cells and their association with HIV-1-induced T cell dysfunction.

Authors:  Brent E Palmer; Naomi Blyveis; Andrew P Fontenot; Cara C Wilson
Journal:  J Immunol       Date:  2005-12-15       Impact factor: 5.422

8.  Murine autoimmune cholangitis requires two hits: cytotoxic KLRG1(+) CD8 effector cells and defective T regulatory cells.

Authors:  Wenting Huang; Kritika Kachapati; David Adams; Yuehong Wu; Patrick S C Leung; Guo-Xiang Yang; Weici Zhang; Aftab A Ansari; Richard A Flavell; M Eric Gershwin; William M Ridgway
Journal:  J Autoimmun       Date:  2014-02-18       Impact factor: 7.094

9.  Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection.

Authors:  P Borrow; H Lewicki; B H Hahn; G M Shaw; M B Oldstone
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

10.  Control of effector CD8+ T cell function by the transcription factor Eomesodermin.

Authors:  Erika L Pearce; Alan C Mullen; Gislâine A Martins; Connie M Krawczyk; Anne S Hutchins; Valerie P Zediak; Monica Banica; Catherine B DiCioccio; Darrick A Gross; Chai-An Mao; Hao Shen; Nezih Cereb; Soo Y Yang; Tullia Lindsten; Janet Rossant; Christopher A Hunter; Steven L Reiner
Journal:  Science       Date:  2003-11-07       Impact factor: 47.728

View more
  37 in total

1.  Acute-Phase CD4+ T Cell Responses Targeting Invariant Viral Regions Are Associated with Control of Live Attenuated Simian Immunodeficiency Virus.

Authors:  Matthew S Sutton; Amy Ellis-Connell; Ryan V Moriarty; Alexis J Balgeman; Dane Gellerup; Gabrielle Barry; Andrea M Weiler; Thomas C Friedrich; Shelby L O'Connor
Journal:  J Virol       Date:  2018-10-12       Impact factor: 5.103

2.  Cancer neoantigens targeted by adoptive T cell transfer: private no more.

Authors:  Enrico Lugli; Pia Kvistborg; Giovanni Galletti
Journal:  J Clin Invest       Date:  2019-02-04       Impact factor: 14.808

3.  A novel SIV gag-specific CD4(+)T-cell clone suppresses SIVmac239 replication in CD4(+)T cells revealing the interplay between antiviral effector cells and their infected targets.

Authors:  Victor I Ayala; Matthew T Trivett; Lori V Coren; Sumiti Jain; Patrick S Bohn; Roger W Wiseman; David H O'Connor; Claes Ohlen; David E Ott
Journal:  Virology       Date:  2016-03-25       Impact factor: 3.616

4.  TGF-β receptor maintains CD4 T helper cell identity during chronic viral infections.

Authors:  Gavin M Lewis; Ellen J Wehrens; Lara Labarta-Bajo; Hendrik Streeck; Elina I Zuniga
Journal:  J Clin Invest       Date:  2016-09-06       Impact factor: 14.808

Review 5.  Clonally expanded cytotoxic CD4+ T cells and the pathogenesis of IgG4-related disease.

Authors:  Hamid Mattoo; John H Stone; Shiv Pillai
Journal:  Autoimmunity       Date:  2017-02       Impact factor: 2.815

6.  The anti-caspase inhibitor Q-VD-OPH prevents AIDS disease progression in SIV-infected rhesus macaques.

Authors:  Mireille Laforge; Ricardo Silvestre; Vasco Rodrigues; Julie Garibal; Laure Campillo-Gimenez; Shahul Mouhamad; Valérie Monceaux; Marie-Christine Cumont; Henintsoa Rabezanahary; Alain Pruvost; Anabela Cordeiro-da-Silva; Bruno Hurtrel; Guido Silvestri; Anna Senik; Jérôme Estaquier
Journal:  J Clin Invest       Date:  2018-03-19       Impact factor: 14.808

7.  Clonal expansion of CD4(+) cytotoxic T lymphocytes in patients with IgG4-related disease.

Authors:  Hamid Mattoo; Vinay S Mahajan; Takashi Maehara; Vikram Deshpande; Emanuel Della-Torre; Zachary S Wallace; Maria Kulikova; Jefte M Drijvers; Joe Daccache; Mollie N Carruthers; Flavia V Castelino; James R Stone; John H Stone; Shiv Pillai
Journal:  J Allergy Clin Immunol       Date:  2016-03-11       Impact factor: 10.793

8.  Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells.

Authors:  Julia A M Sung; Joy Pickeral; Liqin Liu; Sherry A Stanfield-Oakley; Chia-Ying Kao Lam; Carolina Garrido; Justin Pollara; Celia LaBranche; Mattia Bonsignori; M Anthony Moody; Yinhua Yang; Robert Parks; Nancie Archin; Brigitte Allard; Jennifer Kirchherr; JoAnn D Kuruc; Cynthia L Gay; Myron S Cohen; Christina Ochsenbauer; Kelly Soderberg; Hua-Xin Liao; David Montefiori; Paul Moore; Syd Johnson; Scott Koenig; Barton F Haynes; Jeffrey L Nordstrom; David M Margolis; Guido Ferrari
Journal:  J Clin Invest       Date:  2015-09-28       Impact factor: 14.808

9.  Cytomegalovirus Coinfection Is Associated with Increased Vascular-Homing CD57+ CD4 T Cells in HIV Infection.

Authors:  Bonnie Chen; Stephen R Morris; Soumya Panigrahi; Gillian M Michaelson; Jonathan M Wyrick; Alexey A Komissarov; Daria Potashnikova; Anna Lebedeva; Souheil-Antoine Younes; Karem Harth; Vikram S Kashyap; Elena Vasilieva; Leonid Margolis; David A Zidar; Scott F Sieg; Carey L Shive; Nicholas T Funderburg; Sara Gianella; Michael M Lederman; Michael L Freeman
Journal:  J Immunol       Date:  2020-03-30       Impact factor: 5.422

Review 10.  Antigen processing and presentation in HIV infection.

Authors:  Julie Boucau; Sylvie Le Gall
Journal:  Mol Immunol       Date:  2018-04-07       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.